TWST CEO Emily Leproust reports new RSU grant and option holdings
Rhea-AI Filing Summary
Twist Bioscience Corp (TWST) reported a new equity award to its Chief Executive Officer and director, Emily M. Leproust. On 11/18/2025, she received 146,914 shares of common stock in the form of restricted stock units at a reported price of $0 per share, increasing her directly held beneficial ownership to 880,836 common shares.
The RSU grant vests over four years, with 1/16 of the total vesting on each quarterly anniversary of November 20, 2025, subject to continued service. The filing also lists multiple outstanding employee stock options, including options with exercise prices of $8.82, $26.66, $23.33, and $67.85, covering hundreds of thousands of shares with expiration dates between 2027 and 2030. Some older options at $5.95 now show zero remaining shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 146,914 | $0.00 | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 20, 2025 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
FAQ
What did Twist Bioscience (TWST) report in this Form 4 filing?
The filing reports that CEO and director Emily M. Leproust received 146,914 restricted stock units (RSUs) of Twist Bioscience common stock on 11/18/2025, increasing her directly held beneficial ownership to 880,836 shares.
How do the new RSUs for Twist Bioscience CEO Emily Leproust vest?
The 146,914 RSUs vest over a total period of 48 months. 1/16 of the RSUs vest on each quarterly anniversary of November 20, 2025, subject to her continuous service through each vesting date.
What is the reported acquisition price of the new Twist Bioscience RSUs?
The RSU award to Emily Leproust is reported at a price of $0 per share, which is typical for restricted stock units granted as part of equity compensation rather than purchased in the market.
What stock options for Twist Bioscience does Emily Leproust hold according to this filing?
The filing lists several employee stock options, including options with exercise prices of $8.82, $26.66, $23.33, and $67.85. These options relate to underlying common stock and have expiration dates ranging from 09/28/2027 to 08/31/2030, with remaining amounts such as 150,879, 266,539, 131,290, and 64,950 options shown as beneficially owned.
What are the performance stock options mentioned for Twist Bioscience’s CEO?
The filing notes a grant of performance stock options awarded on September 1, 2020, which vested and became exercisable on December 19, 2022 after Emily Leproust met the applicable performance criteria. These are shown as 64,950 options with an exercise price of $67.85 and an expiration date of 08/31/2030.